NCT00355901|TerminatedDMC
Loading search results
Sponsor study identifier
observational
300
14 countries
40
Study Start
September 2006
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
November 2012
Date type not reportedThis date has not been verified as actual or estimated.
To assess the effects of visilizumab on the safety of subsequent salvage therapies in subjects who experienced disease progression in a previous visilizumab study and subsequently received salvage therapy.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
November 2012
Date type not reportedThis date has not been verified as actual or estimated.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
July 21, 2006
Actual (reported)July 25, 2006
Actual (reported)September 2006
Date type not reportedThis date has not been verified as actual or estimated.
November 2012
Date type not reportedThis date has not been verified as actual or estimated.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
San Francisco, California, 94115, United States
Gainesville, Florida, 32610, United States
Atlanta, Georgia, 30342, United States
Louisville, Kentucky, 40202, United States
Worcester, Massachusetts, 01655, United States
Rochester, Minnesota, 55905, United States
St Louis, Missouri, 63110, United States
First Submitted
July 21, 2006
First Posted
July 25, 2006
Study Start
September 2006
Date type not reportedThis date has not been verified as actual or estimated.
Study Completion
November 2012
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Manhasset, New York, 11030, United States
Mineola, New York, 11501, United States
New York, New York, 10021, United States
New York, New York, 10029, United States
Cleveland, Ohio, 44106, United States
Hershey, Pennsylvania, 17033, United States
Charleston, South Carolina, 29425, United States
Salt Lake City, Utah, 84107, United States
Bedford Park, South Australia, Australia
Box Hill, Victoria, Australia
Fremantle, 6160, Australia
Liverpool, 2170, Australia
Vienna, A-1090, Austria
Ghent, B-9000, Belgium
Leuven, 3000, Belgium
Roeselare, 8800, Belgium
Winnipeg, Manitoba, R3A-139, Canada
Hamilton, Ontario, L8N 3Z5, Canada
Brno, Czechia
Prague, Czechia
Amiens, 80054, France
Lille, 59037, France
Paris, 75010, France
Freiburg im Breisgau, D-79106, Germany
Béri Balogh Adám, H-7100, Hungary
Vác, H-2601, Hungary
Vásvari Pál, H-9024, Hungary
Dublin, Ireland
Bologna, 40138, Italy
Amsterdam, 1105 AZ, Netherlands
Oslo, Norway
Tromsø, Norway
Kharkiv, 61001, Ukraine
Last Updated
August 5, 2008
Record last verified: 2008-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: